multi kinase inhibitor

Related by string. multikinase inhibitor * MULTI . multis . Multis . Multi : Multi Million Dollar . Multi Protocol Label . Multi Touch . multi pronged approach / kinases . Kinase . Kinases : Aurora kinase . Bruton tyrosine kinase Btk . VEGF receptor tyrosine kinases . Aurora kinases / Inhibitor . Inhibitors . inhibitors : proton pump inhibitors . proton pump inhibitors PPIs . ACE inhibitors * *

Related by context. All words. (Click for frequent words.) 77 mTOR inhibitor 77 investigational humanized monoclonal antibody 76 PNP inhibitor 76 IgG1 monoclonal antibody 76 receptor tyrosine kinase inhibitor 75 IAP inhibitor 75 selective kinase inhibitor 75 orally administered inhibitor 75 PDE4 inhibitor 74 signal transduction inhibitor 74 Talabostat 74 dasatinib Sprycel ® 74 angiogenesis inhibitor 74 oral prodrug 74 ADP receptor antagonist 74 non nucleoside inhibitor 74 OMP #R# 73 Aflibercept 73 mertansine 73 Daclizumab 73 tyrosine kinase inhibitor 73 reversible inhibitor 73 BRAF inhibitor 73 ENMD # 73 IMiDs R 73 selective orally bioavailable 73 histone deacetylase HDAC inhibitor 73 liposomal formulation 73 targeted radiotherapeutic 73 Vandetanib 73 HSP# inhibitor 72 alpha folate receptor 72 investigational oral inhibitor 72 AAG geldanamycin analog 72 protein kinase inhibitor 72 VEGFR2 inhibitor 72 proteasome inhibitor 72 Tesetaxel 72 pan histone deacetylase 72 CYT# potent vascular disrupting 72 PEGylated Fab fragment 72 CYC# 72 highly selective inhibitor 72 targeted antifolate 72 orally bioavailable 72 kinase inhibitor 72 erlotinib Tarceva ® 72 Aurora kinase inhibitor 72 Pazopanib 72 Sapacitabine 72 humanized monoclonal antibody 71 mTOR mammalian target 71 virus HCV protease inhibitor 71 anti angiogenic agent 71 sorafenib Nexavar 71 alkylating agent 71 Nanobody 71 Archexin 71 MT#/MEDI-# 71 IAP inhibitors 71 radiation sensitizer 71 immunomodulator 71 Enzastaurin 71 plasma kallikrein inhibitor 71 nucleoside analog 71 multikinase inhibitor 71 pertuzumab 71 AKT inhibitor 71 agonistic human 71 Carfilzomib 71 HGS# 71 selective antagonist 71 M2 subunit 71 MAGE A3 ASCI 71 Nexavar ® 71 Panzem R 71 cetuximab Erbitux R 71 thalidomide Thalomid 71 inhaled formulation 71 Irinotecan 71 Denufosol 71 HQK 71 dasatinib Sprycel 71 polymerase inhibitor 71 pan HDAC inhibitor 70 targeting CD# 70 imatinib Gleevec ® 70 YONDELIS 70 Personalized Immunotherapy 70 HCV protease inhibitor 70 Angiocept 70 JAK1 70 AEG# 70 small molecule thrombopoietin 70 HCV NS5B polymerase 70 sorafenib tablets 70 generation purine nucleoside 70 developing Zerenex TM 70 novel histone deacetylase 70 selective inhibitor 70 HCV protease 70 Factor VIIa 70 NS5b 70 LymphoStat B TM 70 Tezampanel 70 kidney urologic 70 docetaxel Taxotere R 70 reslizumab 70 MKC# MT 70 Tarceva TM 70 Kinase Inhibitor 70 small molecule tyrosine 70 enzyme inhibitor 70 peripherally acting 70 specific lectin receptors 70 small molecule glucokinase 70 Sphingomab 70 CCR9 antagonist 70 IMiDs ® 70 HDAC Inhibitor 70 metastatic colorectal 70 Silodosin 70 compound perifosine 70 vinca alkaloid 70 anti secretory 70 chimeric monoclonal antibody 70 systemic RNAi therapeutic 70 CD4 monoclonal antibody 70 novel peptide 70 nilotinib Tasigna ® 70 accumulate preferentially 70 Epratuzumab 70 panitumumab Vectibix 69 R sorafenib tablets 69 lintuzumab SGN 69 sunitinib Sutent ® 69 MKC# MKC# PP 69 PI3K/Akt pathway inhibitor 69 LymphoStat B belimumab 69 vascular disrupting agent 69 Tyrima 69 JAK inhibitors 69 VitiGam 69 proteasome inhibitors 69 sodium glucose cotransporter 69 Zolinza 69 Mipomersen 69 IMA# 69 bevacizumab Avastin ® 69 Anidulafungin 69 oral dual endothelin 69 investigational immunotherapy 69 Phase 1b clinical trials 69 peptidic compound 69 anti amnesic 69 Seliciclib 69 histone deacetylase inhibitor 69 Pertuzumab 69 candidate deforolimus 69 Degarelix 69 LHRH antagonists 69 lexidronam injection 69 Belimumab 69 Annamycin 69 antibody MAb 69 autologous cellular immunotherapy 69 Temsirolimus 69 acyclovir Lauriad R 69 hormone LHRH antagonist 69 Phase #b/#a clinical 69 Squalamine 69 CCX# 69 Thiarabine 69 CDK cyclin dependent 69 Aurora kinase 69 selective immunoproteasome inhibitor 69 Epidermal Growth Factor Receptor 69 Deforolimus 69 Romidepsin 69 peptibody 69 irreversible inhibitor 69 alvespimycin 69 Pradefovir 69 regorafenib 69 Panzem R NCD 69 JAK inhibitor 69 sphingosine 1 69 docetaxel Taxotere ® 69 Rigel R# 69 MGd 69 Ixempra 69 vapreotide acetate 69 small molecule inhibitor 69 novel VDA molecule 69 Blinatumomab 69 SPL# Gel vaginal microbicide 69 ospemifene 68 Dasatinib 68 brivanib 68 immunomodulating 68 vemurafenib 68 forodesine 68 antibody MT# 68 oral proteasome inhibitor 68 MEK inhibitor 68 Ridaforolimus 68 BZL# 68 XL# anticancer compounds 68 Pralatrexate 68 anticancer compound 68 ALN PCS 68 topically applied SEPA 68 PEG SN# 68 Vicinium TM 68 non peptidic protease 68 Sudhir Agrawal D.Phil 68 tumor vascular disrupting 68 Methylnaltrexone 68 Elesclomol 68 selectively inhibits 68 Cobalamin TM mediated 68 Dapagliflozin 68 Epothilones 68 RANK Ligand inhibitor 68 metastatic hormone refractory 68 Aztreonam 68 IMiDs ® compound 68 mGluR4 68 Aplidin 68 FOLOTYN ® 68 Aliskiren 68 small molecule Hedgehog 68 Elvitegravir 68 Tofacitinib 68 paclitaxel Taxol 68 antiangiogenic agent 68 Gleevec resistant 68 triciribine phosphate monohydrate 68 Afatinib 68 humanized monoclonal 68 Aurora Kinase 68 acetonide FA 68 HCD# [002] 68 refractory chronic lymphocytic 68 Curaxin CBLC# 68 FGFR 68 hypereosinophilic syndrome 68 Fc fusion protein 68 Angiolix 68 novel oral anticoagulant 68 epothilones 68 CCR5 antagonist 68 huC# DM4 68 oral dihydropyrimidine dehydrogenase DPD 68 therapeutic monoclonal antibody 68 Ceflatonin 68 sunitinib Sutent 68 developing Zerenex ferric 68 developing Bicifadine serotonin 68 CEQ# 68 PRT# 68 selective modulator 68 psoriasis rheumatoid arthritis 68 luteinizing hormone releasing 68 GW# [003] 68 vascular disrupting agents 68 5 HT3 antagonist 68 Pathway Inhibitor 68 Epothilone D 68 RAS MAPK pathway 68 tubulin inhibitor 68 CYP#A# CYP#D# 68 ABL inhibitor 68 nucleotide analogue 68 Hsp# Inhibitor 68 Ofatumumab 68 RON Notch 68 tyrosine kinase inhibitor TKI 68 investigational monoclonal antibody 68 MET VEGFR2 68 triggers apoptosis programmed 68 TG# [003] 68 IMiD 68 investigational oral 68 oral JAK1 68 oral isoform selective HDAC 68 advanced metastatic renal 68 M# rationally 68 anticancer agent 68 rALLy clinical trial 68 JAK2 inhibitor 68 CD# monoclonal antibody 68 Liprotamase 68 essential thrombocythemia ET 68 fluoroquinolone antibiotic 68 5 HT2A inverse 67 NPC 1C 67 Bosutinib 67 intranasal formulation 67 Nanobody ® 67 5 HT2A serotonin 67 oral ghrelin agonist 67 humanised monoclonal antibody 67 c Raf kinase 67 Laquinimod 67 peripherally restricted 67 anticancer therapeutics 67 beta 1a 67 bevacizumab Avastin R 67 immune stimulatory 67 estrogen receptor antagonist 67 Ocrelizumab 67 PI3K inhibitor 67 cilengitide 67 TREANDA 67 Panzem NCD 67 NS5B polymerase 67 Vidofludimus 67 EGFR tyrosine kinase inhibitor 67 Ixabepilone 67 KSP inhibitor 67 gemcitabine Gemzar 67 Traficet EN 67 D aspartate NMDA receptor 67 volociximab 67 Bafetinib 67 Telik logo TELINTRA 67 5 HT6 receptor 67 Nexavar sorafenib 67 oral nucleoside analogue 67 trastuzumab Herceptin R 67 DU #b 67 Fludara ® 67 IgG1 antibody 67 GVAX ® 67 SUTENT ® 67 CBLC# 67 Iluvien ® 67 potent antiproliferative 67 Pafuramidine 67 evaluating tivozanib 67 Omacetaxine 67 novel immunomodulatory 67 Olaparib 67 hematological cancers 67 immune modulating 67 oral Janus kinase 67 BAY #-# 67 mitogen activated ERK kinase 67 monoclonal antibody IgG1 Mab 67 oral antiviral 67 humanized therapeutic 67 Muraglitazar 67 ALN TTR 67 myelofibrosis polycythemia vera 67 Abiraterone acetate 67 immunomodulatory 67 novel orally administered 67 monoclonal antibody MAb 67 itraconazole Sporanox 67 Zarnestra 67 oropharyngeal candidiasis OPC 67 5 HT4 67 antisense inhibitor 67 Everolimus 67 product candidate Lpathomab 67 vinca alkaloids 67 Bucindolol 67 investigational antibody 67 hypoxia activated prodrug 67 pan BCR ABL 67 cutaneous T 67 Xcytrin R 67 ZOLINZA 67 selective estrogen receptor modulator 67 immunotherapeutic agent 67 Lixivaptan 67 leading oral taxane 67 ocular formulation 67 PKC# 67 ZACTIMA 67 Bezielle 67 delta opioid receptor 67 generation Hsp# inhibitor 67 TKB# 67 Maribavir 67 Luteinizing Hormone Releasing Hormone 67 androgen receptor antagonist 67 Pemetrexed 67 investigational therapies 67 phase IIb trial 67 anti fibrotic 67 polysaccharide polymer 67 TLR9 agonist 67 MTP inhibitor 67 evaluating picoplatin 67 sunitinib malate 67 non thiazolidinedione TZD 67 apoptosis proteins 67 memantine HCl 67 vidofludimus 67 pralatrexate injection folate analogue 67 ARRY # 67 oral ridaforolimus 67 Locked Nucleic Acid 67 paclitaxel Taxol ® 67 Cloretazine 67 investigational HCV polymerase 67 XL# XL# 67 Troxatyl 67 DNA intercalator 67 Teriflunomide 67 bortezomib Velcade 67 TRX1 67 Horizant ™ 67 Hsp# inhibitors 67 Telatinib 67 R vancomycin hydrochloride 67 Pruvel ™ 67 nilotinib Tasigna 67 MEK Inhibitor 67 generation nucleoside analog 67 lipoglycopeptide 67 NS#/#A protease 67 Initiates Enrollment 67 immunotherapeutic vaccine 67 phase IIb clinical 67 potent inhibitor 67 OncoVex 67 Glufosfamide 67 HCV polymerase inhibitors 67 LHRH receptor positive 67 inhibitor PPI 67 Romiplostim 67 Tarvacin TM 67 mapatumumab 67 ALN HPN 67 Factor Receptor 67 factor Xa 67 docetaxel Taxotere 67 oncolytic virus therapies 67 cell lymphoma CTCL 67 HuLuc# 67 oral Hsp# inhibitor 66 PDX pralatrexate 66 immunomodulatory therapy 66 Boceprevir 66 protein tyrosine phosphatase 1B 66 novel topoisomerase 66 Amrubicin 66 fosbretabulin 66 histone deacetylase HDAC 66 GMX# 66 anti CD3 monoclonal 66 sulfonylhydrazine class 66 gastro intestinal inflammation 66 echinocandin 66 MEK inhibitors 66 microtubule inhibitor 66 5 FU leucovorin 66 orally dosed 66 RNAi therapeutic targeting 66 RhuDex R 66 drug conjugate 66 LHRH antagonist 66 SCH # 66 dihydrochloride Tablets 66 class mGluR5 inhibitor 66 mTOR kinase 66 Voreloxin 66 nitric oxide donating 66 Completes Patient Enrollment 66 selective inhibition 66 NU# direct 66 enzastaurin 66 LY# [002] 66 multiple myeloma MM 66 anthracycline taxane 66 adenosine injection 66 cathepsin K inhibitor 66 oral kinase inhibitor 66 compound INCB# 66 alpha 2A adrenergic 66 humanized interleukin 6 66 Preclinical studies suggest 66 ribonucleotide reductase clinically validated 66 ganetespib 66 evaluating satraplatin 66 ThermoDox R 66 HER1 66 Provectus Pharmaceuticals specializes 66 Cabazitaxel 66 humanized antibody 66 R memantine HCl 66 cetuximab Erbitux ® 66 colorectal bladder 66 BRAF inhibitors 66 Bevacizumab 66 Pagoclone 66 Vitrasert R 66 SinuNase ™ 66 vinorelbine tartrate 66 Xeloda ® 66 5 HT2A receptor 66 Gefitinib 66 Zorbtive TM 66 castrate resistant prostate cancer 66 oncolytic 66 Phase 2b Clinical Trial 66 5 HT6 66 otelixizumab 66 adenosine A2A 66 PDE# 66 PARP inhibitor 66 ELACYT 66 somatostatin analogue 66 non nucleoside 66 antibody fragment 66 humanized anti 66 angiotensin analog 66 Orally administered 66 RNA antagonist 66 CDK inhibitor 66 Bavituximab 66 HGS ETR1 mapatumumab 66 ATL# [001] 66 telomerase therapeutic 66 investigational pan BCR 66 phase III isavuconazole 66 Kit CD# positive 66 oncolytic vaccine 66 reversible inhibitors 66 hematological indications 66 selective androgen receptor modulator 66 Quinamed 66 TOCOSOL 66 Trabectedin 66 NS4A 66 fusion inhibitor 66 PSMA ADC 66 investigational protease inhibitor 66 Azedra 66 R Saizen R 66 kinase inhibition 66 mGluR5 negative 66 adalimumab Humira 66 Phase IIb clinical trials 66 Tanespimycin 66 Transdrug ® nanoparticle 66 HuMax EGFr 66 Cloretazine ® 66 THR beta agonist 66 erlotinib Tarceva R 66 octreotide implant 66 Aplidin R 66 Panzem 66 oral anti arrhythmic 66 Tykerb lapatinib 66 Presents Preclinical Data 66 tiapamil 66 gefitinib Iressa 66 Serostim ® 66 hormone gastrin 66 Pruvel TM 66 Achieves Primary Endpoint 66 Myocet 66 histone deacetylase HDAC inhibitors 66 Xanafide 66 Curaxin 66 non nucleoside HCV 66 Exherin 66 Onconase 66 IMC A# 66 2 methoxyestradiol 66 * olmesartan medoxomil 66 CCR2 66 treat male hypogonadism 66 Golimumab 66 PEGylated anti 66 formerly LymphoStat B 66 VALSTAR 66 PI3K/mTOR 66 Receives Orphan Drug Designation 66 OMP #M# 66 Sphingomab TM 66 erlotinib Tarceva 66 INSPIRE Trial Phase III 66 Cetrorelix 66 ONX 66 R roscovitine 66 Febuxostat 66 Phase Ib clinical trials 66 anti PlGF 66 Novel Oral 66 MT# MEDI 66 Interferon alpha 66 TAFA# 66 recurrent NSCLC 66 rHuPH# recombinant human 66 ASONEP TM 66 agent VDA 66 mu opioid receptor antagonist 66 BCG refractory carcinoma 66 PrevOnco 66 R lenalidomide 66 ALN HTT 66 Piperacillin 66 Meets Primary Endpoint 66 Lubiprostone 66 Ophena TM 66 ProMune 66 immunosuppressant drug 66 specific protein tyrosine 66 aflibercept VEGF Trap 66 intravesical infusion therapy 66 SUTENT 66 opioid receptor antagonist 66 Initiates Phase II 66 Sym# 66 KRN# 66 Ceflatonin R 66 anti TNF alpha 66 oral JAK#/JAK# inhibitor 66 rNAPc2 66 DAVANAT 66 antifungal agent 66 sapropterin dihydrochloride 66 pentostatin 66 OXi# 66 Perifosine 66 molecularly targeted 66 TELINTRA 66 progressive metastatic prostate 66 Prodarsan R 66 oral Factor Xa 66 thymidylate synthase 66 investigational compound 66 BiTE antibody 66 IL# PE#QQR 66 diarrhea predominant irritable 66 selectively inhibit replication 66 BiTE ® 66 TRC# 66 Phase 2a Clinical Trial 66 Peginterferon alfa 2b 66 Trastuzumab DM1 66 VQD 66 ALK inhibitor 66 RhuDex ® 66 subcutaneous formulation 66 proprietary polysaccharide 66 XL# XL# XL# 66 topoisomerase II inhibitor 66 Liposomal 66 Alfacell proprietary ribonuclease 66 AVASTIN 66 Investigational Oral 66 ZEVALIN ® 66 cortisol synthesis 66 thetreatment 66 P#X# antagonist 66 Anti VEGF 66 gastrointestinal stromal tumors GIST 66 Sorafenib Nexavar 66 cyclin dependent kinase inhibitor 66 ASG 5ME 66 metastatic castration resistant 66 trastuzumab DM1 66 sapacitabine CYC# 66 octreotide acetate 66 Granted Orphan Drug 66 Torisel 66 BCR ABL inhibitors 66 Pimavanserin 66 isoform selective 66 novel synthetic PEGylated 66 lead Aganocide compound 66 adrenergic regulation 66 MCSP respectively 66 Unit Dose Budesonide 65 inhibits protein synthesis 65 recurrent metastatic ovarian cancer 65 Cetuximab Erbitux 65 myelodysplastic myeloproliferative diseases 65 xenograft models 65 inhibit VEGF 65 YONDELIS R 65 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 65 protein mTOR 65 pancreatic colon 65 Combination REOLYSIN R 65 Ustekinumab 65 cMET 65 NVA# 65 integrin inhibitor 65 antiangiogenesis therapies 65 Friedreich Ataxia FRDA 65 antibody trastuzumab 65 molecular imaging radiopharmaceutical 65 prostate cancer antigen prostatic 65 PSN# [002] 65 vaccines oncolytic virus 65 WX UK1 65 tubulin binding 65 metaglidasen 65 Allovectin 7 65 humanized monoclonal antibodies 65 Vaprisol 65 Onalta ™ 65 histone deacetylase inhibitors 65 DNA methyltransferase inhibitors 65 Vicriviroc 65 cediranib 65 VA# [002] 65 evaluating T DM1 65 JAK2 Inhibitor 65 Campath alemtuzumab 65 Proxinium TM 65 immune modulatory 65 selective serotonin 2C receptor 65 Aganocide ® 65 LY# [003] 65 Begins Dosing 65 stable nucleic acid 65 alefacept 65 histone methyltransferases HMTs 65 apoptosis inducer 65 non porcine pancreatic 65 Crofelemer budesonide foam 65 XmAb ® 65 CTAP# Capsules 65 personalized cellular immunotherapy 65 opioid induced bowel dysfunction 65 injectable formulation 65 candidate CRLX# 65 Valopicitabine 65 oral anticancer 65 HGS ETR2 65 demethylating agent 65 Tumour Vascular Disrupting Agent 65 modified glutathione analog 65 signal transduction inhibitors 65 Crizotinib 65 modulator SERM 65 XmAb# 65 OMNARIS HFA 65 Safinamide 65 Darinaparsin 65 intravesical instillation 65 BCR ABL inhibitor 65 inhibits Akt activation 65 GRN# 65 Cethromycin 65 methylnaltrexone bromide 65 Chemophase 65 herpetic keratitis 65 Amplimexon 65 Vfend 65 familial amyloidotic polyneuropathy FAP 65 injectable intravascular contrast 65 Clevudine 65 neratinib 65 Solazed ™ 65 selective relaxant 65 monoclonal antibody conjugated 65 leukemia AML 65 brand ciclesonide HFA 65 mild vasodilator 65 Opterone R 65 4 PDE4 enzyme 65 ZD# [001] 65 novel antibody therapeutics 65 secretory phospholipase A2 65 generation proteasome inhibitor 65 poly ADP ribose polymerase 65 ketolide antibiotic 65 sulindac 65 Mitoxantrone 65 Alocrest 65 immunotherapeutic 65 vorinostat 65 Hedgehog Pathway Inhibitor 65 EGFR pathway 65 BAL# [002] 65 FUSILEV enhances 65 Janus kinase 65 preclinically 65 mTOR inhibitors 65 small molecule chemotherapeutic 65 chronic eosinophilic leukemia 65 imatinib Gleevec 65 selective phosphodiesterase 65 Omnitarg 65 long acting muscarinic 65 Akt inhibitor 65 5 fluorouracil leucovorin 65 depsipeptide 65 Phase Ib II 65 delivers fluocinolone acetonide FA 65 IRX 2 65 pathophysiological effects 65 polymerase inhibitors 65 superficial bladder cancer 65 IMC #B 65 bevacizumab Avastin 65 seliciclib CYC# 65 anthracycline derivative 65 Besivance 65 developed preclinically 65 PHX# 65 deforolimus 65 TNF Tumor Necrosis Factor 65 neuronal nicotinic receptor NNR 65 antitumoral 65 rasagiline tablets 65 nucleotide analog 65 RGB # 65 Intravenous CP 65 midstage trials 65 neuraminidase inhibitor 65 Virulizin ® 65 pregabalin Lyrica 65 OHR/AVR# 65 p# inhibitor 65 SNT MC# 65 Albuferon TM 65 PF # [002] 65 compound ISA# 65 neuroprotectant 65 Phase IIb Trial 65 Pegloticase 65 topical antifungal 65 ixabepilone 65 novel tubulin binding 65 OncoVEX GM CSF 65 GSK '# 65 oral chemotherapeutic agent 65 Intravenous Human 65 HuCAL PLATINUM ® CysDisplay 65 neovascular diseases 65 antisense drug 65 including eniluracil ADH 65 BAL# [001] 65 Sorafenib 65 NEUGENE 65 Mg Usa 65 dependent kinase inhibitor 65 FLT3 65 multitargeted 65 Azacitidine 65 hyaluronidase enzyme 65 basiliximab 65 nucleoside analogue 65 candidate DB# 65 CINQUIL 65 Litx 65 Copegus R 65 Hsp# inhibition 65 Actemra tocilizumab 65 Atripla combines 65 Aztreonam lysine 65 HIV integrase inhibitors 65 Vidaza R 65 enhance ApoA 65 Ep CAM 65 SPRYCEL ® 65 Lenocta 65 TRANSDUR ™ 65 ELADUR ™ 65 angiogenesis inhibition 65 dimebon latrepirdine 65 active AKT inhibitor 65 phase IIa clinical 65 SERMs 65 Delafloxacin 65 Raf kinase 65 chemotherapeutic drug 65 Investigational Treatment 65 Alvine Pharmaceuticals 65 potent anticancer 65 Ambrisentan 65 vitreoretinal disorders 65 CB2 selective receptor agonist 65 investigational oral hepatitis C 65 Herceptin trastuzumab 65 Smac mimetics 65 Pyridorin 65 FUSILEV ® 65 azoles 65 DDP# 65 Tarvacin 65 dermatology therapies 65 MAbs targeting 65 HCV polymerase 65 gastrointestinal stromal tumors 65 highly selective endothelin 65 Vidaza azacitidine 65 PEGylated interferon 65 anidulafungin 65 Phase Ib study 65 Plicera 65 siRNA therapeutics 65 rxRNA 65 HDAC inhibitor 65 alfa 2a 65 Campath ® 65 indinavir Crixivan 65 CYP#A# isoenzyme 65 #I TM# 65 FOLFOX6 chemotherapy regimen 65 small molecule agonists 65 Palifosfamide 65 bortezomib Velcade R 65 novel emulsion formulation 65 binds selectively 65 gamma secretase inhibitor 65 PLK1 SNALP 65 Guanilib 65 Cethrin R 65 Elotuzumab 65 mitotic kinesin 65 Recombinant interferon alpha 65 IMPDH inhibitor 65 selective inverse agonist 65 investigational antiplatelet agent 65 Melphalan 65 Bruton tyrosine kinase 65 thrombin inhibitor 65 topical gel formulation 65 oral salmon calcitonin 65 defensin mimetic antibiotic 65 Symadex 64 biologic therapy 64 prokinetic agent 64 #HT# 64 mGluR2 positive 64 markets Gelclair R 64 PD LID 64 DNAi 64 anticancer agents 64 product platforms AZX# 64 HER2 ErbB2 64 HepDirect prodrug 64 interferon gamma 1b 64 DP VPA 64 TELINTRA R 64 HCV NS3 protease 64 TLR8 agonist 64 Fleximer 64 Velcade bortezomib 64 paclitaxel poliglumex 64 MyVax R 64 PLX# 64 Ovitrelle R Serostim 64 including HGF ErbB3 64 NXL# 64 trastuzumab DM1 T DM1 64 cyclin dependent kinase CDK 64 TRANSDUR ® 64 taxane derivative 64 GLPG# 64 chemically modified siRNA 64 R roscovitine CDK cyclin 64 relapsed leukemia 64 histamine dihydrochloride 64 metastatic colorectal carcinoma 64 synthetic retinoid 64 obatoclax 64 nitric oxide donating prostaglandin 64 Tyrosine Kinase Inhibitor 64 lenalidomide Revlimid R 64 trastuzumab Herceptin 64 Lenocta TM 64 BENLYSTA ® 64 selective agonist 64 Zoraxel TM 64 recurrent glioblastoma multiforme 64 demonstrated antitumor activity 64 generation antisense 64 dexpramipexole 64 somatostatin analog 64 CYT# vascular disrupting 64 Camptosar ® 64 relapsed refractory multiple myeloma 64 ERBITUX cetuximab 64 gemcitabine Gemzar ® 64 mGluR2 NAM 64 metastatic malignant 64 estramustine 64 Rasagiline 64 PNT# 64 toenail onychomycosis 64 prostate cancer HRPC 64 TOCOSOL Camptothecin 64 JAK2 inhibitors 64 oxazolidinone 64 BRIM2 64 CA4P 64 chemotherapeutic agent

Back to home page